Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
Revenue
Intra-Cellular Therapies Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Revenue
$464.4m
|
CAGR 3-Years
173%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
67%
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Intra-Cellular Therapies Inc
Revenue Breakdown
Breakdown by Geography
Intra-Cellular Therapies Inc
Breakdown by Segments
Intra-Cellular Therapies Inc
Total Revenue:
464.4m
USD
|
Product Sales, Net:
462.2m
USD
|
Grant Revenue:
2.2m
USD
|
See Also
What is Intra-Cellular Therapies Inc's Revenue?
Revenue
464.4m
USD
Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Revenue amounts to 464.4m USD.
What is Intra-Cellular Therapies Inc's Revenue growth rate?
Revenue CAGR 10Y
67%
Over the last year, the Revenue growth was 86%. The average annual Revenue growth rates for Intra-Cellular Therapies Inc have been 173% over the past three years , and 67% over the past ten years .